Back to the Top
Dear Dr Stumpf,
I think all my statements & claims were qualified and placed in the
context of finding out more about imaging mass spectrometry (IMS) in
drug development and I tried to balance this between "provocative" and
You seemingly remain unconvinced of the potential and possibilities of
IMS and perhaps one of the reasons is that this is a very recent
technological development. Therefore, "validation" is in its infancy
(as with all new techniques). Similarly, the support & evidence base
that you mentioned can never be compared on an equal footing with that
of older methodologies that have been around for yonks.
Having said that mass spectrometry, in all its different forms, has
been around for yonks, since J.J. Thompson (around 1900) and 5 Nobel
Prizes have been awarded in the 20th century for efforts in this
(large) area. Besides recent developments such as IMS there has been a
large increase in the number of peer-reviewed papers on MS
applications in the fields of metabolomics and proteomics. The
multitude of applications, which quite often can be performed on one
and the same piece of equipment (with minor modifications), and the
fact that MS detection can be ultra-sensitive, is highly selective,
and nearly universal (i.e. all molecules have a measurable mass) makes
this so attractive.
I did include a couple of links for anyone who wants to broaden their
horizon and to get some feedback on IMS and its potential place or use
in drug development.
I have yet to see one post that meets this goal (i.e. specific
feedback on IMS).
This thread has been hijacked by me and we should close it, don't you
think? Alternatively, we start a new one. After all, this is a
["from previous thread: Does half-life in blood inform about drug
targets" - db]
Want to post a follow-up message on this topic?
If this link does not work with your browser send a follow-up message to PharmPK@boomer.org with "Imaging MS in drug development" as the subject
Support PharmPK by using the
Copyright 1995-2011 David W. A. Bourne (firstname.lastname@example.org)